

Additional file 1: Trials of oral dexketoprofen in pain after third molar extraction pain

| Reference | Methods | Details | Dosing regimen | Outcomes | Efficacy Results | Remedication, exclusions, and adverse events | Safety results | Quality score |
|--|---|---|--|---|--|---|---|---------------------|
| Gay et al. Analgesic Efficacy of Low Doses of Dexketoprofen in the Dental Pain Model. Clin Drug Invest 1996; 11: 320-330 | RCT, DB, single oral dose, parallel groups, LA, 12 hr analgesic washout | Third molar extraction N= 206 2 centres (Barcelona and Spain) | Dexketoprofen tromethamine 5mg N= 41 | Pain intensity 100mm VAS | Dexketoprofen tromethamine 5mg SPID6 (VAS) 77.9 ± 127.2 TOTPAR6 9.8 ± 6.4 Global good/excellent 59% Time to onset 2.8 ± 2.6 Time to remedication 300.4 ± 96.7 No remedication 14 | Remedication permitted, LOCF for patients remedication 1hr or more into study | Dexketoprofen tromethamine 5mg No with >1 AE 3 All cause withdrawals 0 AE withdrawals 0 | R 1 DB 2 WD 1 |
| | | | Dexketoprofen tromethamine 10mg N= 42 | Pain intensity 4-pt VRS (1-absent, 2- mild, 3 - moderate, 4 - severe) | Time to onset 2.8 ± 2.6 Time to remedication 300.4 ± 96.7 No remedication 14 | 2 patients excluded from ITT analysis for remedication within 1 hr | AE withdrawals 0 | Total = 4 |
| | | | Dexketoprofen tromethamine 20mg N= 41 | Pain relief 5-pt VRS (0 - nil, 1 - slight, 2 - moderate, 3 - considerable, 4 - complete) | Dexketoprofen tromethamine 10mg SPID6 96.7 ± 158.8 TOTPAR6 10.5 ± 6.7 Global good/excellent 68% Time to onset 1.7 ± 2.3 Time to remedication 289.6 ± 93.3 No remedication 20 | A total of 17 patients reported 27 adverse events, all were minor and no patient withdrew as a result | Dexketoprofen tromethamine 10mg No with >1 AE 2 All cause withdrawals 0 AE withdrawals 0 | OPVS = 13/16 |
| | | | Ibuprofen 400mg N= 41 | Time to remedication | Global good/excellent 68% Time to onset 1.7 ± 2.3 Time to remedication 289.6 ± 93.3 No remedication 20 | | Dexketoprofen tromethamine 20mg No with >1 AE 5 All cause withdrawals 0 AE withdrawals 0 | |
| | | | Placebo N= 41 | Patient global 4-pt VRS (useless, mediocre, good, excellent) | No remedication 20 | | Ibuprofen 400mg No with >1 AE 3 All cause withdrawals 0 AE withdrawals 0 | |
| | | | | | Dexketoprofen tromethamine 20mg SPID6 109.8 ± 129.3 TOTPAR6 11.3 ± 6.4 Global good/excellent 68% Time to onset 0.9 ± 1.3 Time to remedication 302.3 ± 85.7 No remedication 18 | | Placebo No with >1 AE 4 All cause withdrawals 2 AE withdrawals 0 | |
| | | | | | ibuprofen 400mg SPID6 148.7 ± 153.6 TOTPAR6 13.6 ± 7.5 Global good/excellent 78% Time to onset 2.1 ± 2.3 Time to remedication 302.6 ± 106.1 No remedication 11 | | | |
| | | | | | Placebo SPID6 (VAS) -19.5 ± 141.7 TOTPAR6 5.2 ± 5.8 Global good/excellent 29% Time to onset 4.0 ± 2.6 Time to remedication 218.9 ± 122.7 No remedication 26 | | | |
| | | | | | All three dexketoprofen doses and ibuprofen significantly better than placebo | | | |

| | | | | | | | | |
|--|--|---|---|---|--|--|--|--|
| McGurk et al. Clinical comparison of dextketoprofen trometamol, ketoprofen, and placebo in postoperative dental pain. J Clin Pharmacol 1998; 38 (Suppl): 46S-54S | RCT, DB, single oral dose, parallel groups, LA, 12 hr analgesic washout Assessed at baseline, 10, 20, 30 and 45 mins, and 1, 1.5, 2, 3, 4, 5, 6 hrs Medication administered when pain was of moderate to severe intensity and within 3 hrs of surgery | Third molar extraction N= 210 10 centres in the UK, 1 centre in Germany | Dextketoprofen trometamol 12.5mg N= 44 | Pain intensity 100mm VAS | Dextketoprofen trometamol 12.5mg SPID6 7.07 ± 16.44 TOTPAR6 10.2 ± 7.27 Global good/excellent 58% Time to max PID 2.0 ± 1.5 Time to remedication 4.9 ± 1.6 No remedication 41% | Remedication permitted, LOCF for patients remedication 1hr or more into study, patients remedication within 1 hr were excluded from analyses 10 patients were excluded; 3 due to remedication within 1 hr and 7 because they failed to return the patient diary card A total of 35 events were reported by 28 patients, there were no statistically significant differences between groups and the majority were mild, 2 patients withdrew as a results of adverse events | Dextketoprofen trometamol 12.5mg No with >1 AE 4 AE withdrawals 0 Dextketoprofen trometamol 25mg No with >1 AE 4 AE withdrawals 0 Dextketoprofen trometamol 50mg No with >1 AE 7 AE withdrawals 0 Ketoprofen (racemic) No with >1 AE 5 AE withdrawals 1 Placebo No with >1 AE 8 AE withdrawals 1 | R 2 DB 2 WD 1 Total = 5 OPVS = 13/16 |
| | | | Dextketoprofen trometamol 25mg N= 41 | Pain intensity 4-pt VRS (1-absent, 2- mild, 3 - moderate, 4 - severe) | | | | |
| | | | Dextketoprofen trometamol 50mg N= 43 | Pain relief 5-pt VRS (0 - nil, 1 - slight, 2 - moderate, 3 - considerable, 4 - complete) | Dextketoprofen trometamol 25mg SPID6 4.84 ± 4.4 TOTPAR6 12.61 ± 6.13 Global good/excellent 65% Time to max PID 1.8 ± 1.2 Time to remedication 5.3 ± 1.3 No remedication 27% | | | |
| | | | Ketoprofen 50 mg (racemic) N= 43 | Patient assessment of whether pain reduced by 50% from baseline Time to remedication | | | | |
| | | | Placebo N= 39 | Patient global 4-pt VRS (ineffective, mediocre, good, excellent) | Dextketoprofen trometamol 50mg SPID6 4.52 ± 4.78 TOTPAR6 12.3 ± 6.7 Global good/excellent 78% Time to max PID 2.5 ± 1.8 Time to remedication 5.4 ± 1.1 No remedication 24% Ketoprofen (racemic) SPID6 4.16 ± 4.62 TOTPAR6 12.16 ± 6.17 Global good/excellent 60% Time to max PID 2.5 ± 1.9 Time to remedication 5.5 ± 1.4 No remedication 15% Placebo SPID6 -1.92 ± 4.79 TOTPAR6 3.23 ± 4.77 Global good/excellent 12% Time to max PID 1.1 ± 1.6 Time to remedication 3.6 ± 2.0 No remedication 79% All active treatments significantly better than placebo | | | |
| Bagán et al. Clinical comparison of dextketoprofen trometamol and dipyron in postoperative dental pain. J Clin Pharmacol 1998; 38 (Suppl): 55S-64S | RCT, DB, multiple oral dose, parallel groups, LA, 12 hr analgesic washout Single-dose phase; assessed at baseline, 15, and 30 mins, and 1, 2, 3, 4, 5, 6 hrs Multi-dose phase; assessed immediately before and 2 hr after each dose Medication administered when pain was of moderate to severe intensity and within 3 hrs of surgery Repeat doses (2 to 12) could be taken at least 6 hrs apart, more than 4 times a day for 3 days | Third molar extraction N= 125 4 centres in Spain | Dextketoprofen trometamol 12.5mg N= 38 | Pain intensity 100mm VAS | Dextketoprofen trometamol 12.5mg SPID6 4.8 ± 3.6 TOTPAR6 10.7 ± 6.6 Global good/excellent 82% Time to max PID 108.6 ± 90.4 Time to remedication 335.2 ± 57.5 No remedication 12 | Remedication permitted, LOCF (pain intensity) and 'none' (pain relief) for patients withdrawing 1hr or more into the study, patients remedication within 1 hr were excluded from analyses. Patients only included in the repeated-dose phase if they did not remedicate within the first 6 hrs. Patients remedication at any point during the repeated dose phase were withdrawn 5 patients were excluded from single dose phase; 1 patient failed to take study medication, 1 patient remedicated within 1 hr, 3 patients reported only mild baseline pain 13 patients reported a total of 18 adverse events, there were no adverse events leading to withdrawal, does not state if results are from single-dose phase only or both phases | Dextketoprofen trometamol 12.5mg No with >1 AE 8 AE withdrawals 0 Dextketoprofen trometamol 25mg No with >1 AE 7 AE withdrawals 0 Dipyron 575mg No with >1 AE 3 AE withdrawals 0 | R 1 DB 2 WD 1 Total = 5 OPVS = 13/16 |
| | | | Dextketoprofen trometamol 25mg N= 42 | Pain intensity 4-pt VRS (0 - no pain to 3 - severe pain) | | | | |
| | | | Dipyron 575mg N= 40 | Pain relief 5-pt VRS (0 - no relief to 4 - complete relief) | Dextketoprofen trometamol 25mg SPID6 5.3 ± 4.1 TOTPAR6 13 ± 5.8 Global good/excellent 90% Time to max PID 135.4 ± 96.3 Time to remedication 333.7 ± 69.1 No remedication 8 | | | |
| | | | | Patient global 4-pt VRS (poor, fair, good, excellent) | | | | |
| | | | | Time to remedication | Dipyron 575mg SPID6 3.5 ± 4.6 TOTPAR6 8.5 ± 8.2 Global good/excellent 44% Time to max PID 73.1 ± 72.1 Time to remedication 301.1 ± 94.7 No remedication 19 Both dextketoprofen doses significantly better | | | |

| | | | | | | | |
|--|--|--------------------------------|---|---|---|---|---|
| Jackson et al. Double-blind, randomised, placebo-controlled trial comparing rofecoxib with dextketoprofen trometamol in surgical dentistry. Br J Anaesth 2004; 92:675-680. | RCT, DB, single oral dose, parallel groups, LA, 12 hr analgesic washout | Third molar extraction | Dextketoprofen trometamol 25mg N= 42 | Pain intensity 100mm VAS | Dextketoprofen trometamol 25mg SPID8 6.9 ± 3.9 TOTPAR8 463.9 ± 169.8 Global8 good/excellent 3 (2 - 4) Time to remedication 398 (251 - 630) No remedication 35 | Remedication permitted, does not state how missing values handled only that ANOVA and Bonferroni's correction for multiple comparisons were applied | Dextketoprofen trometamol 25mg R 1 DB 2 WD 1 |
| | Assessed at baseline, 15, 30, and 45 mins, and 1, 2, 3, 4, 5, 6, 7 and 24 hrs | N= 120 1 centre in Scotland | Rofecoxib 50mg N= 37 | Pain intensity 4-pt VRS (1 - absent, 2 - mild, 3 - moderate, 4 - severe) | | | AE withdrawals 0 |
| | Medication administered when pain was of moderate to severe intensity and within 4 hrs of surgery | | Placebo N= 43 | Pain relief 100mm VAS Pain relief 5-pt VRS (1 - none, 2 - a little, 3 - some, 4 - a lot, 5 - complete) Patient global 5-pt VRS (1 - poor, 5 - excellent) | Rofecoxib 50mg SPID8 8.128 ± 3.86 TOTPAR8 502.4 ± 163.1 Global8 good/excellent 4 (3 - 4) Time to remedication 1440 (425 - 1440) No remedication 15 Placebo SPID8 4.25 ± 4.96 TOTPAR8 361.5 ± 182.8 Global8 good/excellent 2 (1-3) Time to remedication 150 (88 - 256) No remedication 36 | 7 patients were excluded; 4 patients failed to develop sufficient pain, no data were available for 2 patients, 1 patient was not dosed due to severe nausea 15 patients reported 20 adverse events, there were no adverse events leading to withdrawal | Total = 4 OPVS = 13/16 |
| Jiménez-Martínez et al. Estudio de la eficacia analgésica del Dextketoprofeno trometamol 25 mg vs Ibuprofeno 600 mg tras su administración oral en pacientes sometidos a una intervención quirúrgica oral. Med Oral 2004; 9: 138-48. | RCT, multiple oral dose, parallel groups, 24 hr analgesic washout | Third molar extraction | Dextketoprofen trometamol 25mg N= 47 | Pain intensity 100mm VAS | Both active drugs significantly better than Not reported | Not reported | R 1 DB 0 WD 0 |
| | Assessed at baseline, 1, 6 and 8 hrs after drug administration | N= 93 1 centre in Spain | Ibuprofen 600mg N= 46 | Pain intensity VRS | Impossible to interpret results, as differences in no or mild pain between groups | | Total = 1 |
| | Medication administered 2 hrs after surgery (unless pain occurred sooner although 26 patients didn't take until after 2 hrs) and then every 8 hrs; states that pain presented by patient after surgery but before treatment was used as a reference, results describe mild pain so baseline pain not moderate to severe in intensity | | | | | | OPVS = 7/16 |

| | | | | | | | | |
|--|--|--------------------------------|--|--|---|---|---|---------------------|
| Harrison F. Dental Pain study of dextketoprofen 12.5 mg and 25 mg versus placebo. (data from clinical trial report) | RCT, DB, single oral dose, parallel groups, LA, 12 hr analgesic washout | Third molar extraction | Dextketoprofen tromethamine 12.5 mg N= 49 | Pain intensity 100mm VAS | Dextketoprofen tromethamine 12.5 mg SPID6 3.97 TOTPAR6 10.6 | 4 patients were excluded from ITT analyses as they remedicated within the 1st hr | Dextketoprofen tromethamine 12.5 mg No with >1 AE 6 All cause withdrawals 16 AE withdrawals 0 | R 2 DB 2 WD 1 |
| | Assessed at baseline, 10, 20, 30 and 45 mins, and 1, 1.5, 2, 3, 4, 5 and 6 hrs | N= 141 6 centres in Germany | Dextketoprofen tromethamine 25 mg N= 46 | Pain intensity 4-pt VRS (absent, mild, moderate, severe) | Global good/excellent 27 Time to max PID 2.02 Time to remedication 5.4 No remedicating | | Dextketoprofen tromethamine 25 mg No with >1 AE 7 All cause withdrawals 9 AE withdrawals 1 | Total = 5 |
| | Medication administered when pain was of moderate to severe intensity and within 3 hrs of surgery | | Placebo N= 46 | Pain relief 5-pt VRS (no pain relief, slight pain relief, moderate pain relief, considerable pain relief, complete pain relief) | Dextketoprofen tromethamine 25 mg SPID6 5.15 TOTPAR6 12.35 Global good/excellent 28 Time to max PID 2.39 Time to remedication No remedicating | | Placebo No with >1 AE 6 All cause withdrawals 21 AE withdrawals 0 | OPVS = 13/16 |
| | | | | Percentage pain relief | | | | |
| | | | | Patient global 4-pt VRS (null, mediocre, good, excellent) | Placebo SPID6 0.28 TOTPAR6 5.18 Global good/excellent 9 Time to max PID 1.77 Time to remedication 4.33 No remedicating 5.71 | | | |
| | | | | | Both dextketoprofen doses significantly better than placebo | | | |
| Munoz et al. Preoperative dextketoprofen trometamol for the prevention of postoperative dental pain: a randomized double-blind clinical study. Methods and Findings in Experimental and Clinical Pharmacology 1998; 20 (Suppl A):69. (abstract) Data from clinical trial report [Berini et al. Clinical trial to assess the analgesic efficacy of a single oral administration of LM-1158. TRIS in the prevention of post-operative pain. Clinical trial report 1999] | RCT, DB, DD, single oral dose, parallel groups, | Third molar extraction | Dextketoprofen trometamol 25mg pre-surgery N= 51 | Pain intensity 100mm VAS | Dextketoprofen trometamol 25mg pre-surgery SPID8 236.21 ±167 SPID4 67.44 ± 63.14) Global good/excellent 34 | Remedication permitted, patients remedicating within 1 hr were excluded from analyses, after 1 hr LOCF used to input missing values | Dextketoprofen trometamol 25mg pre-surgery No with >1 AE 1 All cause withdrawals AE withdrawals 0 | R 2 DB 2 WD 1 |
| | Assessed at baseline (30 mins after surgery), 10, 20, 30 and 45 mins, and 1, 1.5, 2, 3, 4, 5, 6, 7 and 8 hrs | N= 102 1 centre in Spain | Dextketoprofen trometamol 25mg post-surgery N= 51 | Pain intensity 4-pt VRS (zero, mild, moderate, severe) | Time to min pain intensity 10.21 ± 30.23 Time to remedication 282.18 ± 82.6 No remedicating 17 | | 3 adverse events were reported, all were of mild intensity, no serious adverse events were reported | Total = 5 |
| | Medication administered either 30 mins pre-surgery or 30 mins post surgery | | | Patient global 4-pt VRS (null, mediocre, good, excellent) | Dextketoprofen trometamol 25mg post-surgery SPID8 196.69 ± 155.35 SPID4 68.93 ± 56.1 Global good/excellent 42 Time to min pain intensity 21.25 ± 38.68 Time to remedication 339 ± 84.7 No remedicating 14 | | Dextketoprofen trometamol 25mg post-surgery No with >1 AE 2 All cause withdrawals AE withdrawals 0 | OPVS = 13/16 |
| | | | | Time to remedication | | | | |
| | | | | | No significant differences | | | |

Abbreviations: RCT = randomised controlled trial; R = randomised; DB = double blind; wD = withdrawal or dropout; OPVS = Oxford Pain validity Score; LOCF - last observation carried forward; ITT = intention to treat; N = number; LA = local anaesthetic; VAS = visual analogue scale; VRS = verbal rating scale; AE = adverse event; SPID = summed pain intensity difference; TOTPAR = total pain relief